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No single animal model for severe acute respiratory syndrome (SARS) reproduces all aspects of the human disease.
Young inbred mice support SARS-coronavirus (SARS-CoV) replication in the respiratory tract and are available in
sufficient numbers for statistical evaluation. They are relatively inexpensive and easily accessible, but their use in SARS
research is limited because they do not develop illness following infection. Older (12- to 14-mo-old) BALB/c mice
develop clinical illness and pneumonitis, but they can be hard to procure, and immune senescence complicates
pathogenesis studies. We adapted the SARS-CoV (Urbani strain) by serial passage in the respiratory tract of young
BALB/c mice. Fifteen passages resulted in a virus (MA15) that is lethal for mice following intranasal inoculation.
Lethality is preceded by rapid and high titer viral replication in lungs, viremia, and dissemination of virus to
extrapulmonary sites accompanied by lymphopenia, neutrophilia, and pathological changes in the lungs. Abundant
viral antigen is extensively distributed in bronchial epithelial cells and alveolar pneumocytes, and necrotic cellular
debris is present in airways and alveoli, with only mild and focal pneumonitis. These observations suggest that mice
infected with MA15 die from an overwhelming viral infection with extensive, virally mediated destruction of
pneumocytes and ciliated epithelial cells. The MA15 virus has six coding mutations associated with adaptation and
increased virulence; when introduced into a recombinant SARS-CoV, these mutations result in a highly virulent and
lethal virus (rMA15), duplicating the phenotype of the biologically derived MA15 virus. Intranasal inoculation with
MA15 reproduces many aspects of disease seen in severe human cases of SARS. The availability of the MA15 virus will
enhance the use of the mouse model for SARS because infection with MA15 causes morbidity, mortality, and
pulmonary pathology. This virus will be of value as a stringent challenge in evaluation of the efficacy of vaccines and
antivirals.
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Introduction
The occurrence in late 2002 and early 2003 of cases of
severe acute respiratory syndrome (SARS) in southeast China
quickly drew international attention as the disease sickened
more than 8,000 people and spread to more than 30 countries
within six months. Since the identification of the etiological
agent, the SARS-coronavirus (SARS-CoV), in 2003, develop-
ment and characterization of animal models for evaluation of
prophylaxis and treatment strategies have been of great
interest. Although SARS-CoV has not been associated with a
subsequent widespread outbreak since 2002–2003, the po-
tential for such an outbreak remains. Identification of a
SARS-like coronavirus in Chinese horseshoe bats (Rhinolophus
species) that are indigenous across Southeast Asia suggests
that they may represent a natural reservoir from which
viruses may be introduced into the human population [1].
The course of infection in animal models is abbreviated
compared with the course of SARS in humans; however, many
aspects of SARS-CoV–associated disease are reproducible in
animal models, including age-dependent susceptibility, re-
covery of SARS-CoV from respiratory tissues and secretions,
infection of type I and type II pneumocytes and bronchial
epithelial cells, detection of viral genome in blood and
extrapulmonary tissues, and pulmonary pathology (including
pneumonitis, edema, necrotic debris, and hyaline membrane
formation) [2,3]. Clinical symptoms have been reported in
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some species, but the findings are not entirely reproducible
in outbred species. Variability in clinical symptoms seen in
outbred species may result from additional factors, including
infection with co-pathogens, stress, existence of sub-species
of test animals, and use of different virus strains. This
variation can be problematic in studies of pathogenesis and
vaccine efficacy unless a large enough number of animals are
included in each treatment group [2]. The ideal animal model
would demonstrate viral replication in respiratory tissues,
histopathologic evidence of respiratory disease, and consis-
tent clinical signs of disease, including mortality. A small
animal model in which all of these aspects of virus-associated
disease are seen would be desirable because reproducible
data can be generated in inbred animals, and larger numbers
of animals can be included for statistical analysis of biological
outcomes.
To generate a model that satisfies these criteria, we have
serially passaged SARS-CoV in the respiratory tract of young
BALB/c mice, resulting in a lethal virus that causes dose-
dependent weight loss and mortality associated with higher
viral titers in the respiratory tract than are seen with the wild-
type virus and with histopathologic findings of severe
pulmonary disease. The characteristics of this lethal mouse-
adapted SARS-CoV, (MA15), are reported here.
Results
Adaptation of SARS-CoV for Increased Virulence in a
Young BALB/c Mouse Model
Adaptation of SARS-CoV (Urbani) was achieved by serial
passage through lungs of BALB/c mice as previously described
for influenza A and influenza B viruses [4,5]. Lightly
anesthetized mice were inoculated intranasally with 105
50% tissue culture infectious dose (TCID50) per mouse of
SARS-CoV (Urbani). Two to three days post-infection (d.p.i.),
when peak viral titers are observed, lungs were harvested
from infected mice and clarified homogenates were used as
inocula for continued serial passage via intranasal inocu-
lation in mice. To screen for virulence in mice, groups of
young naı¨ve mice (N ¼ 5–8) were inoculated with lung
homogenates collected at passage 2, 10, and 15 (P2, P10, and
P15, respectively), weighed daily, and observed twice daily for
signs of morbidity or mortality. Deaths were not observed
following inoculation with P2 or P10; however, increased
morbidity, as indicated by weight loss, was noted in P10-
inoculated mice at day 3 post-infection (p.i.) (unpublished
data). Mortality was observed in P15-inoculated mice; 60% of
P15-inoculated mice died or displayed extreme morbidity
and were euthanized by 5 d.p.i. Mortality was not observed in
mice infected with intermediate passages (P11–P14), and
accompanying morbidity was not measured (unpublished
data). Supernatant from lung homogenates at P15 contained
a heterogeneous virus pool as evident upon sequence analysis
of cDNA fragments generated by reverse transcriptase PCR
(RT-PCR) amplification from purified viral RNA (vRNA).
Dual peaks were observed on sequence chromatograms at
several nucleotide residues, indicating mixed populations in
the virus pool. To obtain a clonal population, P15 virus was
biologically cloned by three rounds of terminal dilution in
Vero cells. Five clones were screened for lethality in 6- to 8-
wk-old BALB/c mice; these clones caused mortality from 50%
to 100%. One clone, designated MA15, resulted in 100%
mortality within 6 d. BALB/c mice aged 6 to 8 wk, 4 mo, and
13 mo were all susceptible to MA15 infection, with severe
morbidity or death occurring within 3 to 5 d following
intranasal inoculation.
Mutations Identified in the Mouse-Adapted Virus
In order to identify the mutations in MA15 associated with
the lethal phenotype, the sequence of MA15 was compared
with that of SARS-CoV (Urbani). The sequence of the initial
SARS-CoV (P0) virus was identical to the published SARS-
CoV (Urbani) sequence, and six nucleotide substitutions were
identified in the MA15 genome compared with that of SARS-
CoV (Urbani). All six substitutions were predicted to cause
amino acid substitutions. These six mutations were localized
to open reading frame (ORF) 1ab (four mutations) and ORFs
S and M (one each) of SARS-CoV (Figure 1). Independent
analysis conducted by The Institute for Genomic Research
(Rockville, Maryland, United States), under a National
Institute of Allergy and Infectious Diseases (NIAID) contract,
confirmed the same six mutations in the MA15 sequence
compared with those in the SARS-CoV (Urbani) sequence.
Generation of Recombinant Clones
To confirm that the six mutations identified in the MA15
virus were responsible for lethality in mice, the mutations
were introduced into cDNA clones from which recombinant
SARS-CoVs were recovered. Sequence analysis confirmed
that recombinant viruses contained the appropriate muta-
tion sets that were derived from the MA15 virus. In addition
to generating a recombinant virus that included the six
mutations (rMA15), two additional recombinants were
generated containing either the two mutations in the
structural protein genes or the four mutations in the ORF
1ab (rMA15SM and rMA15ORF1ab, respectively).
MA15 and Recombinant Viruses Replicate In Vitro with
Similar Kinetics
The three recombinant viruses demonstrated similar
kinetics and levels of viral replication compared with that
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Author Summary
Severe acute respiratory syndrome (SARS) is a severe, sometimes
fatal respiratory disease caused by a coronavirus (SARS-CoV). In
order to study the disease and evaluate vaccines and antiviral drugs,
animal models that mimic the disease are necessary. However, no
single animal model for SARS reproduces all aspects of the disease
as it affects humans. SARS-CoV replicates in the lungs of young
mice, but they do not show signs of illness. Adaptation of SARS-CoV
by serial passage in the lungs of mice resulted in a virus (MA15) that
is lethal for young mice following intranasal inoculation. Lethality is
preceded by rapid and high titer viral replication in lungs, viremia,
and dissemination of virus to extrapulmonary sites accompanied by
hematological changes and pathological changes in the lungs. Mice
infected with MA15 virus die from an overwhelming viral infection
with extensive, virally mediated destruction of pneumocytes, and
ciliated epithelial cells. The MA15 virus has six coding mutations in
its genome, which, when introduced into a recombinant SARS-CoV,
confer lethality. The MA15 virus will enhance the use of the mouse
model for SARS because infection with this virus in mice reproduces
many aspects of severe human disease, including morbidity,
mortality, and pulmonary pathology.
of SARS-CoV infectious clone (icSARS-CoV), a wild-type
recombinant SARS-CoV (Urbani) generated from cDNAs, the
biologically derived MA15 virus, and SARS-CoV (Urbani) in
in vitro single-cycle growth analyses in Vero E6 cells. At a
multiplicity of infection (MOI) of 0.1, viruses reached peak
replication (107.0–7.5 pfu/mL) at ;24 h.p.i., with a slight delay
in peak titers for rMA15ORF1ab (Figure S1). Northern blot
analysis of RNA from infected Vero E6 cells indicated that
genomic vRNA and viral mRNA and all eight sub-genomic
mRNAs were present in similar ratios for the recombinant
viruses and MA15 virus as for SARS-CoV (Urbani) (Figure
2A). The level of expression and mobility of the structural
proteins (S and N) and an accessory protein (ORF 3a, also
called X1) of the recombinant viruses and MA15 virus were
comparable to those of SARS-CoV (Urbani), as determined by
Western blot analysis (Figure 2B). Although S, N, and X1 are
somewhat reduced in the lane (Figure 2B) from icSARS-CoV–
infected cultures, this is associated with reduced amounts of
total protein added to the well, rather than with any specific
reduction in X1 expression. Thus, the recombinant viruses
(rMA15SM, rMA15ORF1ab, rMA15, and icSARS-CoV) and the
MA15 virus demonstrate no defects in replication or in RNA
or protein expression compared with SARS-CoV (Urbani) in
Vero E6 cells.
Replication of MA15 and rMA15 in Mice
Groups of naı¨ve mice were inoculated with serial 10-fold
dilutions of MA15 virus, and the dose-dependent weight loss
and lethality observed following infection is summarized in
Table 1. Mice receiving a dose 103.9 TCID50 of MA15 virus
died or lost more than 20% of their initial body weight
between days 3 and 5 p.i. Mice experiencing weight loss in
excess of 20% initial body weight are euthanized in
accordance with our animal study protocol. The 50% lethal
dose (LD50) was 10
4.6 TCID50. At an intermediate, non-lethal
dose (102.9/mouse), mice lost 8.4% 6 2.5% of initial body
weight by day 4 p.i. At a lower dose, weight loss was not
significant (4.3% 6 1.0% by day 4 p.i.)
Similarly, groups of naı¨ve mice were inoculated with serial
10-fold dilutions of rMA15, rMA15ORF1ab, or rMA15SM, and
followed daily for signs of morbidity (indicated by weight loss)
and mortality. Mortality was observed only in rMA15-
inoculated mice at doses equal to or in excess of 104.4
TCID50/mouse (Table 1). The LD50 for rMA15 of 10
3.9 TCID50
is similar to the LD50 observed for the MA15 virus. Consistent
with observations following infection with MA15 virus,
mice inoculated with low concentrations of rMA15 (100.4–2.4
TCID50/mouse) had little to no significant weight loss, but an
intermediate dose of rMA15 (103.4 TCID50/mouse) resulted in
significant weight loss but no mortality. Thus rMA15 reca-
pitulated the phenotype of the MA15 virus in mice. Inocu-
lation with the highest doses of rMA15SM and rMA15ORF1ab
(106.2 TCID50/mouse) did not result in mortality (Table 2), and
only rMA15ORF1ab-infected mice demonstrated significant
morbidity as indicated by weight loss.
The rapid lethality observed following administration of
MA15 virus (or its recombinant clone rMA15) to BALB/c mice
could result from changes in tissue tropism with or without
viremia, increased viral load and subsequent necrosis in
pulmonary or extrapulmonary tissues, failure of innate or
early adaptive immune responses, immunopathology in
pulmonary or extrapulmonary tissues, or a combination of
these or other factors. In order to evaluate whether changes
in tissue tropism or levels of viral replication could
contribute to the lethal phenotype of the MA15 virus, viral
titers in lungs, spleen, liver, and brain of BALB/c mice were
determined at various time points following intranasal
inoculation with SARS-CoV (Urbani) or MA15.
Efficient Replication of MA15 Virus in Pulmonary Tissues
Mice were inoculated intranasally with SARS-CoV (Urbani)
(105 TCID50/mouse, a dose that results in peak viral titers in
lungs of mice 2 d.p.i.) or with lethal (105.6 TCID50/mouse) or
Figure 1. Schematic Diagram of SARS-CoV Genome Indicating Mutations Found in MA15 Virus
(A) The 29,727 nucleotide positive-sense RNA genome of SARS-CoV is depicted in this to-scale drawing with ORFs indicated by shaded boxes (dark gray,
structural and non-structural proteins; light gray, accessory genes X1–X5 [37]; and straight lines, non-coding regions). Asterisks indicate the sites of the
six nucleotide changes (compared with the published SARS-CoV (Urbani) sequence) resulting in six coding mutations found in the mouse-adapted
SARS-CoV (MA15).
(B) The six mutations found in MA15. aORF, open reading frame. bCDS, coding sequence, sequence of nucleotides that corresponds with the sequence
of amino acids in a protein (location includes start and stop codon). cnsp, non-structural protein, cleavage product of ORF 1ab; Mainpro, main 3C-like
protease; Hel, helicase. dRBM, receptor binding motif (amino acids 424–494).
doi: 10.1371/journal.ppat.0030005.g001
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sub-lethal (103.6 TCID50/mouse) doses of MA15 virus. At
various time points p.i., mice were sacrificed and tissues
harvested for subsequent processing. Data from replicate
experiments were combined. High titers of virus were
detected in the lungs of mice through day 5 p.i. (Figure 3).
One day after inoculation, the amount of SARS-CoV (Urbani)
in lungs was;106 TCID50/g tissue. Following administration of
a lethal dose, MA15 virus was found to replicate to significantly
higher titers of ;109 TCID50/g tissue within 24 h (p¼ 0.0001;
Figure 3). In this study and in previous studies (K. Subbarao, A.
Roberts, L. Vogel, E. Lamirande, et al., unpublished data), peak
virus titers (;107.0 TCID50/g tissue) occur at day 2 following
inoculation with SARS-CoV (Urbani). In comparison, by day 2
p.i., viral titers in MA15-inoculated mice reached, or persisted
at, titers of ;109 TCID50/g tissue, regardless of inoculating
dose (Figure 3). Furthermore, in mice inoculated with a sub-
lethal dose of MA15, virus was detected at 107.7 TCID50/g lung
on day 5 p.i. By comparison, in SARS-CoV (Urbani)–infected
mice, virus was detected at titers of 105.1 TCID50/g lung on day
5 p.i. By 6 d.p.i., virus was no longer consistently detected in
mice inoculated with SARS-CoV (Urbani) or with sub-lethal
doses of MA15 virus (Figure 3).
Table 1. Morbidity and Mortality in Mice following Intranasal Administration of MA15 and Recombinant MA15 Viruses
Virus
Administered
Dose
(log10 TCID50/Mouse)
Maximum %
Weight Loss
Day p.i. to Maximum
Weight Loss or Death
LD50
(log10 TCID50/Mouse)
MA15 virus 1.9 4 4 4.6
2.9 9 5–6
3.9 .20 4–5
4.9 .20 4–5
5.9 .20 3–5
6.9 .20 3–4
rMA15 0.4 ,3 NA 3.9
1.4 4 4
2.4 3 3–4
3.4 12 4
4.4 .20 5
5.4 .20 4–5
6.4 .20 4–5
NA, not applicable.
doi:10.1371/journal.ppat.0030005.t001
Figure 2. Recombinant SARS-CoVs Demonstrate Normal Processing of vRNAs and Proteins
(A) Northern analysis. Intracellular RNA was isolated 10.5 h.p.i. from Vero E6 cells infected with indicated viruses or from mock-infected cells. RNA (0.1
lg) was treated with glyoxal, separated on 1% agarose gel, transferred to a BrightStar-Plus membrane, and probed with an N gene–specific biotinylated
oligomer as described in Materials and Methods.
(B) Western analysis. Cell lysates were separated on two 7.5% SDS-PAGE gels, transferred to polyvinylidene fluoride and probed with either mouse anti-S
antisera (top panel) or probed first with a mouse anti-X1 antisera (sera raised to accessory protein X1 [37]; middle panel), and then stripped and probed
again with a mouse anti-N antisera (bottom panel). Each primary antibody was followed by goat anti-mouse HRP-conjugated secondary antibody and
visualized by enhanced chemiluminescence.
doi:10.1371/journal.ppat.0030005.g002
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MA15 Virus Detected in Extrapulmonary Tissues
Following inoculation with a lethal dose of MA15 virus,
virus was also recovered from spleen, brain, and liver from
day 1 through day 4 p.i. at titers ranging from 101.8 to 102.7
TCID50/g (brain) and from 10
1.8 to 103.3 TCID50/g (spleen)
(Table 3). Virus was detected more frequently in the liver and
at higher titers (102.1–104.3 TCID50/g) than in brain or spleen.
Virus was not recovered from any of these organs following
inoculation with SARS-CoV (Urbani), except in one mouse,
sacrificed 5 d.p.i., in which virus was detected in the spleen at
a titer just above the limit of detection (Table 3). Although
the levels of viral replication detected in these tissues in
MA15-infected mice are modest, the number of mice in which
virus was detected is remarkable, and both the frequency and
the titers are significantly higher than those observed in
SARS-CoV (Urbani)–infected mice.
In a separate experiment, infectious virus was also detected
in sera of mice infected with MA15 virus or recombinant
SARS-CoVs on days 2 and 4 p.i. Data from this experiment
suggest that the presence of virus in serum may be facilitated
by the mutations in the S and M genes, since virus was
detected more frequently and at higher titers in sera from
mice infected with MA15, rMA15, or rMA15SM than in sera
from mice infected with icSARS-CoV or MA15ORF1ab (Figure
S2).
vRNA Detected in Pulmonary and Extrapulmonary Tissues
In addition to recovery of infectious virus from these
tissues, total RNA was also isolated from whole blood, brain,
kidney, liver, intestine, spleen, thymus, heart, and lungs of
BALB/c mice after infection. Although quantitative virology
holds biological relevance since it indicates viral burden by
measuring infectious virus, RT-PCR of vRNA or sub-genomic
mRNAs may be more sensitive assays for the presence of
virus. Due to the replication strategy of SARS-CoV, primers
that specifically amplify sub-genomic mRNAs allow detection
of products of viral transcription. Furthermore, amplification
of virus-specific mRNAs allows distinction from vRNA that
may represent non-viable virus [6]. RT-PCR amplification of
genomic, antigenomic, and sub-genomic mRNA-specific
sequences was employed to confirm the presence of SARS-
CoV nucleic acid or viral transcription products in different
tissues.
Groups of four mice were inoculated with a lethal dose of
MA15 virus or with SARS-CoV (Urbani) (105 TCID50/mouse).
Mice inoculated with MA15 virus did not survive past day 4
p.i. SARS-CoV (Urbani)–infected mice were followed through
day 14 p.i. vRNA, and viral mRNA were amplified from lungs
of MA15-infected mice on days 1–4 p.i. In contrast, vRNA was
amplified from SARS-CoV (Urbani)–infected mice through
day 14 p.i., but mRNA, indicating viral transcription, was
consistently amplified only through day 5 p.i. mRNA was
detected as late as day 7 p.i. by RT-PCR in one of four of the
SARS-CoV (Urbani)–infected mice (Tables 4 and 5).
We were also able to amplify vRNA and mRNA from blood,
brain, thymus, heart, and spleen of MA15-infected mice
(Tables 4 and 5). Viral mRNA was consistently detected by
RT-PCR in the tissues of MA15-inoculated mice from day 2
p.i. through day 4 p.i. and in the thymus and heart of MA15-
infected mice as early as day 1 p.i. In contrast, vRNA and viral
mRNA were detected transiently in very few SARS-CoV
(Urbani)–infected mice and only in the blood, spleen, and
Table 2. Morbidity and Mortality in Mice following Intranasal Administration of MA15 and Recombinant Viruses
Virus
Administereda
Maximum Percent
Weight Loss
Day p.i. to Maximum
Weight Loss or Death
Number Surviving/
Number Inoculated
(Percent Mortality)
icSARS-CoV ,3 NA 12/12 (0)
rMA15SM ,3 NA 12/12 (0)
rMA15ORF1ab 10 NA 12/12 (0)
rMA15 .20 4 2/12 (83)
MA15 .20 4 0/13 (100)
a6.2 log10 TCID50/mouse.
NA, not applicable.
doi:10.1371/journal.ppat.0030005.t002
Figure 3. Virus Titers in Lungs of BALB/c Mice Inoculated with SARS-CoV
or MA15 Virus
Data represents a compilation of two experiments. In each experiment,
groups of four mice were inoculated intranasally with 50 lL of SARS-CoV
(Urbani) (105.0 TCID50/mouse, black bars) or MA15 virus at lethal (10
5.6
TCID50/mouse, white bars) or sub-lethal (10
3.6 TCID50/mouse, light gray
bars) doses. Mice were sacrificed on indicated d.p.i. Mice receiving lethal
doses of MA15 virus did not survive beyond day 4. Bars represent mean
viral titers; error bars indicate standard error. Asterisks indicate significant
differences (p, 0.05) compared with titers in mice receiving lethal doses
of MA15 virus. Dotted line indicates lower limit of detection (101.5
TCID50/g).
doi:10.1371/journal.ppat.0030005.g003
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thymus. vRNA and viral mRNA were not detected by RT-PCR
analysis in liver, intestines, or kidneys from MA15 or SARS-
CoV (Urbani)–infected mice. These tissues may contain
factors that inhibit RT-PCR amplification of SARS-CoV
RNAs, since virus was isolated from liver homogenates of
MA15-infected mice but was not detected by RT-PCR, and
viral mRNA was detected in intestines by in situ hybridization
(unpublished data). In summary, virus or viral-specific RNA
was detected in blood, lung, thymus, brain, spleen, liver, and
heart from almost all MA15-infected mice. In contrast, virus
or viral-specific RNA was detected in the lungs, and only
sporadically in blood, spleen, and thymus from SARS-CoV
(Urbani)–infected mice (Tables 3–5).
Histopathologic and Immunohistochemical Findings
The lungs of mice infected with SARS-CoV (Urbani)
showed a rapid progression from focal, mild, perivascular,
and peribronchiolar mononuclear inflammatory cell infil-
trates to a diffuse, but transient, interstitial pneumonitis on
day 3 p.i. (Figure 4A, 4C, 4E, and 4G). Occasional ciliated
columnar epithelial cells of the bronchioles and alveolar
pneumocytes stained for viral antigen by immunohistochem-
istry (IHC) (Figure 5A, 5C, 5E, and 5G). No viral antigens were
detected at day 14 p.i., and most mice at this time point
showed no significant pulmonary histopathology (unpub-
lished data).
In comparison, the pulmonary pathology of mice infected
with MA15 virus showed a rapid progression of inflammatory
changes (Figure 4B, 4D, 4F, and 4H), but with more extensive
damage to bronchiolar and alveolar epithelial cells (Figure 6A
and 6B). These changes were especially evident in pneumo-
cytes, and many detached, pyknotic, and necrotic cells were
identified in alveolar spaces (Figure 6A). Inflammatory
infiltrates, although consistently identified, were generally
similar in intensity to those observed in the lungs of SARS-
CoV (Urbani)–infected mice (Figure 4). However, the distri-
bution and amount of viral antigens identified by IHC was far
greater in the lungs of MA15-infected mice than in the lungs
of mice infected with SARS-CoV (Urbani) (Figure 5). Intra-
cellular SARS-CoV antigens were extensively and abundantly
distributed in bronchiolar epithelium, alveolar pneumocytes,
and in necrotic debris within the alveoli and bronchiole
lumens of MA15-infected mice (Figure 6C and 6D).
No significant histopathologic changes were identified in
extrapulmonary organs, including the liver, spleen, thymus,
or brain, of mice infected with SARS-CoV (Urbani) or MA15
virus. Furthermore, SARS-CoV antigens were not detected in
any of these tissues by IHC staining.
Changes in Blood Counts and Chemistry in MA15-Infected
Mice
Infection of young BALB/c mice with 106.4 TCID50/mouse of
MA15 virus resulted in elevated levels of the liver enzyme
alkaline phosphatase (ALP) in sera collected on days 1–6 p.i.
ALP levels were significantly higher in sera of MA15-
inoculated mice than they were in pre-infection sera from
the same mice. Serum ALP levels in MA15-inoculated mice
were also significantly higher than those of mice inoculated
with 106.4 TCID50/mouse of SARS-CoV (p¼ 0.0045; Table S5).
Levels of other liver enzymes, including aspartate amino-
transferase, alanine aminotransferase, gamma glutamyl trans-
ferase, creatine kinase, urea nitrogen, total bilirubin, and
albumin, were not significantly altered following inoculation
with MA15 virus (unpublished data). Although moderately
elevated levels of creatinine were observed in MA15-
inoculated mice, no significant differences were seen between
MA15- and SARS-CoV–inoculated mice, suggesting that this
was not associated with the lethal phenotype of the MA15
virus. Furthermore, significant lymphopenia and neutrophilia
were observed following infection with SARS-CoV and MA15
virus. Although some samples were lost due to coagulation of
blood, the alterations in the lymphocyte and neutrophil
counts were more severe following infection with MA15 virus
than they were following SARS-CoV infection (Table S5).
Primary Infection with SARS-CoV (Urbani) Protects Mice
from Lethal Challenge with MA15 Virus
In order to determine whether MA15 virus can be used as a
more stringent challenge in evaluating vaccines and antiviral
therapy designed for SARS-CoV than could the non-lethal
SARS-CoV (Urbani), we inoculated eight mice with 50 lL of
SARS-CoV (Urbani) at 105 TCID50/mouse and mock-immu-
nized an additional eight mice. Four weeks after inoculation,
the mice were bled for determination of SARS-CoV–specific
serum neutralizing antibodies and challenged with 106.9
TCID50 of MA15 virus. Mice were followed daily for signs of
Table 3. Detection of SARS-CoV and MA15 Infectious Virus
Day following
Inoculation
Number of Mice in Which Virus Was Detected/Number Tested in Indicated Organ
Lung Brain Spleen Thymus Heart Liver Blood
SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15
1 4/4 4/4 0/4 3/4 0/4 3/4 — — — — 0/4 2/4 — —
2 4/4 4/4 0/4 2/4 0/4 4/4 — — — — 0/4 4/4 — —
3 4/4 4/4 0/4 1/4 0/4 1/4 — — — — 0/4 3/4 — —
4 4/4 4/4 0/4 2/4 0/4 1/4 — — — — 0/4 3/4 — —
5 3/4 — 0/4 — 1/4 — — — — — 0/4 — — —
7 2/4 — 0/4 — 0/4 — — — — — 0/4 — — —
9 0/4 — 0/4 — 0/4 — — — — — 0/4 — — —
14 0/4 — 0/4 — 0/4 — — — — — 0/4 — — —
doi:10.1371/journal.ppat.0030005.t003
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morbidity and mortality. Serum neutralizing antibodies were
detected at low titers (1:10) in SARS-CoV–immunized mice
but not in mock-immunized mice (,1:8). Nevertheless, SARS-
CoV–immunized mice were protected from lethal challenge
and demonstrated reduced morbidity (;11% weight loss
compared with .20% weight loss in mock-immunized mice)
following a high titer challenge with MA15 virus. Mock-
immunized mice did not survive past day 4 following
challenge with MA15 virus (Figure 7).
Discussion
Serial passage of SARS-CoV (Urbani) in the lungs of BALB/
c mice resulted in a mouse-adapted SARS-CoV (MA15 virus)
that is lethal for young (6- to 8-wk-old) BALB/c mice. The
virulence and lethality of the MA15 virus result from six
mutations in the SARS-CoV genome that occurred within 15
passages through BALB/c mice. Introduction of these six
mutations into a recombinant SARS-CoV infectious clone,
rMA15, conferred a lethal phenotype on the virus for young
BALB/c mice. Five of these six mutations (not including the
T67A mutation occurring in the non-structural protein [nsp]
9 of ORF 1ab) occur within nsp 5 (two mutations), nsp 13, S,
and M. These genes have been reported as ones where
sequence evolution occurred during adaptation of SARS-CoV
in humans [7]. The mutations in nsp 9, nsp 5 (H133Y and
E269A within the main protease, 3CLpro), and nsp 13 (A4V
within the helicase protein) do not occur within any known
functional domains and do not alter known cleavage sites
utilized in the processing of the ORF 1ab polyprotein.
Furthermore, the mutations in the MA15 virus do not occur
at any specific amino acid positions identified by the Chinese
SARS Molecular Epidemiology Consortium [7]. Only the
mutation in S (Y436H) occurs within a known functional
domain, the receptor-binding motif (RBM). Other reports
have indicated that mutations within the RBM may account
for increased affinity of the virus for its cellular receptor
angiotensin converting enzyme 2 [8]. However, the Y436H
mutation in MA15 virus does not occur at previously
identified sites of the RBM and angiotensin converting
enzyme 2 interaction, and preliminary findings suggest that
the Y436H mutation does not increase binding of the SARS-
CoV (Tor2) RBD to murine angiotensin–converting enzyme 2
[9].
Table 4. Detection of SARS-CoV and MA15 vRNA
Day following
Inoculation
Number of Mice in Which RNA Was Detected/Number Tested in Indicated Organ
Lung Brain Spleen Thymus Heart Liver Blood
SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15
1 4/4 4/4 0/4 0/4 0/4 0/4 1/3 3/4 0/4 3/4 0/4 0/4 0/4 0/4
2 4/4 4/4 0/4 4/4 0/4 4/4 0/1 3/4 0/4 4/4 0/4 0/4 0/4 4/4
3 4/4 4/4 0/4 4/4 0/4 3/4 0/2 3/4 0/4 4/4 0/4 0/4 2/4 4/4
4 4/4 4/4 0/4 4/4 2/4 4/4 1/3 4/4 0/4 4/4 0/4 0/4 0/4 3/4
5 4/4 — — — — — — — — — — — — —
7 4/4 — — — — — — — — — — — — —
9 4/4 — — — — — — — — — — — — —
14 4/4 — — — — — — — — — — — — —
Amplification of vRNA used primer pairs For28411 and Rev28725.
doi:10.1371/journal.ppat.0030005.t004
Table 5. Detection of SARS-CoV and MA15 mRNA
Day following
Inoculation
Number of Mice in Which RNA Was Detected/Number Tested in Indicated Organ
Lung Brain Spleen Thymus Heart Liver Blood
SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15 SARS-
CoV
MA15
1 4/4 4/4 0/4 0/4 0/4 0/4 1/3 3/4 0/4 3/4 0/4 0/4 0/4 0/4
2 4/4 4/4 0/4 3/4 0/4 2/4 0/1 3/4 0/4 4/4 0/4 0/4 0/4 4/4
3 4/4 4/4 0/4 4/4 0/4 2/4 0/2 2/4 0/4 3/4 0/4 0/4 2/4 3/4
4 4/4 4/4 0/4 4/4 1/4 2/4 1/3 4/4 0/4 3/4 0/4 0/4 0/4 3/4
5 3/4 — — — — — — — — — — — — —
7 1/4 — — — — — — — — — — — — —
9 0/4 — — — — — — — — — — — — —
14 0/4 — — — — — — — — — — — — —
Amplification of mRNA used primer pairs PCR-L and Rev28509.
doi:10.1371/journal.ppat.0030005.t005
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Reports of adaptation of an influenza A virus for increased
virulence in mice indicate that multiple gene products may
interact or contribute independently to virulence. In one
adaptation of influenza A/FM/1/47 (FM-MA), findings indi-
cated that four viral gene segments contributed to increased
virulence [4], but additional analyses indicated that mutations
occurring in at least two and likely three gene products acted
synergistically to account for the increased virulence [10–12].
Recombinant icSARS-CoV produced mild pneumonia iden-
tified by X-ray changes in macaques, similar to the clinical
disease noted with wild-type SARS-CoV (Urbani) [13].
Consistent with these findings, recombinant SARS-CoV
bearing the six novel mouse-adapted mutations, rMA15,
recapitulated a fatal respiratory disease phenotype in mice,
demonstrating the ability of the SARS molecular clones to
capture complex disease phenotypes. We generated two other
recombinant SARS-CoVs, rMA15SM (encoding the two muta-
tions in the S and M genes) and rMA15 ORF1ab (encoding the
four mutations in ORF 1ab). Neither of these was lethal
(Table 2) in BALB/c mice, indicating that SARS-CoV
adaptation for BALB/c mice involves mutations in at least
two and possibly three genes (SþORF 1ab, MþORF 1ab, or S
þM þ ORF 1ab). Although recombinant viruses bearing two
or four of the mutations were not lethal, each had a different
Figure 4. Histopathological Changes in Lungs from SARS-CoV (Urbani)–Infected and MA15-Infected Mice (Hematoxylin and Eosin Stain, Original
Magnifications325)
Day 1 p.i. (A) SARS-CoV (Urbani)–infected mice: no significant inflammatory cell infiltrates. (B) MA15-infected mice: foci of perivascular, peribronchiolar,
and interstitial inflammatory infiltrates comprised predominantly of mononuclear cells.
Day 2 p.i. (C) Same as in (A). (D) MA15-infected mice: small, mononuclear inflammatory cell focus in the alveolar interstitium.
Day 3 p.i. (E) SARS-CoV (Urbani)–infected mice: extensive and confluent interstitial pneumonitis. (F) MA15-infected mice: mild interstitial inflammation
with diffuse pyknosis and karyorrhexis of alveolar pneumocytes.
Day 4 p.i. (G) SARS-CoV (Urbani)–infected mice: small, discrete inflammatory cell infiltrates involving the alveolar interstitium. (H) MA15-infected mice:
mild interstitial inflammation and necrotic intraalveolar debris. Mice were inoculated with 105.6 TCID50 MA15 virus/mouse or 10
5.0 TCID50 SARS-CoV
(Urbani)/mouse.
doi:10.1371/journal.ppat.0030005.g004
PLoS Pathogens | www.plospathogens.org January 2007 | Volume 3 | Issue 1 | e50030
Mouse-Adapted SARS-CoV Lethal in BALB/c Mice
phenotype than that of SARS-CoV (Urbani). It is possible that
the mutations in S and M contribute to increased viremia
(Figure S2) and that the mutations in ORF 1ab contribute to
increased pathogenicity indicated by weight loss (Table 2).
Both quantitative virology and IHC analysis of the lungs of
MA15-infected mice indicate extraordinarily high levels of
viral replication in pulmonary tissues as early as 24 h.p.i., and
the level of replication remains high through day 4 p.i. Unlike
SARS-CoV–infected mice, in which viral antigen is detected
by IHC staining at modest levels in bronchial epithelium and
in alveolar pneumocytes on days 1 and 2 p.i., the bronchial
epithelium of MA15-infected mice is replete with viral
antigen at day 1 p.i., as are alveolar pneumocytes on days 1
and 2 p.i. By day 3 p.i., viral antigen is rarely detected in the
Figure 5. Immunohistochemical Staining for SARS-CoV Antigen in Lungs of SARS-CoV(Urbani)–Infected or MA15-Infected Mice
Immunohistochemical staining is shown in red.
Day 1 p.i. (A) SARS-CoV (Urbani)–infected mice: antigen present in occasional ciliated respiratory epithelial cells in bronchioles. (B) MA15-infected mice:
diffuse and extensive staining of bronchiolar respiratory epithelium and alveolar pneumocytes.
Day 2 p.i. (C) SARS-CoV (Urbani)–infected mice: staining of occasional bronchiolar epithelial cells and rare alveolar pneumocytes. (D) MA15-infected
mice: staining predominantly in intact and detached cells in pulmonary alveoli.
Day 3 p.i. (E) SARS-CoV (Urbani)–infected mice: occasional staining of alveolar pneumocytes and bronchiolar epithelium. (F) MA15-infected mice:
extensive staining of abundant, intraalveolar, necrotic debris.
Day 4 p.i. (G) SARS-CoV (Urbani)–infected mice: occasional focus of predominantly pneumocyte staining. (H) MA15-infected mice: extensive staining of
abundant, intraalveolar, necrotic debris. Primary antibody, rabbit anti-SARS-CoV antibody; secondary antibody conjugated with alkaline phosphatase
with naphthol fast-red and hematoxylin counterstain; original magnifications325. Mice were inoculated with 105.6 TCID50 MA15 virus/mouse or 10
5.0
TCID50 SARS-CoV (Urbani)/mouse.
doi:10.1371/journal.ppat.0030005.g005
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lungs of SARS-CoV–infected mice; in contrast, viral antigen
remains abundant in pneumocytes, necrotic debris, and
pyknotic cells in MA15-infected mice through day 4 p.i.
In this model, day 3 to day 4 p.i. seems to be a critical time
for the outcome of SARS-CoV infection. SARS-CoV (Ur-
bani)–infected mice demonstrate a pronounced but transient
interstitial inflammation at day 3 p.i. that is absent in MA15-
infected mice. This transient inflammation is not associated
with significant weight loss but coincides with the beginning
of viral clearance from the lungs. In contrast, by day 3 p.i.,
MA15 virus–infected mice lose weight, and necrotic cellular
debris begins to fill the bronchioles and alveoli. By day 4 p.i.,
MA15-infected mice have lost in excess of 20% of their initial
body weight, and several die without other overt clinical signs
such as ataxia, paralysis, hunched posture, etc. Viral titers in
lungs of MA15-infected mice are up to 1,000-fold higher than
those in SARS-CoV–infected mice by 24 h.p.i. and remain
higher than peak levels in SARS-CoV–infected mice through
day 4 p.i. In situ hybridization further confirms the intense
and persistent signal of MA15 (and rMA15) vRNA in lung
tissues at day 4 p.i. when vRNA from SARS-CoV (Urbani) and
the non-lethal rMA15SM and rMA15ORF1ab viruses are less
abundant (Figure S3). Objective data related to respiratory
distress such as plethysmography and measurement of blood
gases could not be collected because of practical and
logistical constraints on experiments carried out in an
Animal Biosafety Level 3 laboratory. However, our findings
indicate that MA15 virus–infected mice die as a result of
overwhelming pulmonary viral infection and destruction of
bronchiolar epithelial cells and alveolar pneumocytes. Viral
load in SARS cases was an important determinant of severe
disease and death [14], but the mechanism of disease leading
to fatal outcome in human cases of SARS may be different
than that observed in MA15-infected BALB/c mice. The
mechanism of death following SARS-CoV infection in
humans, and particularly the relative contribution of virus-
induced damage and immunopathology, are not fully under-
Figure 6. Histopathology and Immunohistochemical Localization of SARS-CoV Antigens in the Lungs of Mice Infected with MA15 Virus
Abundant necrotic cellular debris (arrows) in alveoli (A) and a bronchiole lumen (B) of mice at days 2 and 3 p.i., respectively. Abundant SARS-CoV
antigens (arrowheads) within alveolar pneumocytes (C) and in necrotic alveolar and bronchiolar cellular debris in mice at day 2 p.i. (D).
(A and B) Hematoxylin and eosin stain; (C and D) primary antibody, rabbit anti-SARS-CoV antibody; secondary antibody conjugated with alkaline
phosphatase with naphthol fast-red and hematoxylin counterstain; original magnifications3100. Mice were inoculated with 105.6 TCID50 MA15 virus/mouse.
doi:10.1371/journal.ppat.0030005.g006
Figure 7. Challenge of SARS-CoV– or Mock-Immunized Mice with the
Lethal MA15 Virus
Groups of eight mice (8 wk old) were immunized intranasally with 50 lL
of SARS-CoV (Urbani) (105TCID50/mouse) or L15 tissue culture media.
Four weeks after immunization, mice were challenged intranasally with
50 lL MA15 virus (106.9 TCID50/mouse), weighed daily, and observed
twice daily for morbidity and mortality. Surviving mice that lost in excess
of 20% initial body weight were euthanized. Symbols represent mean
values for SARS-CoV–immunized mice (triangles) and mock-immunized
mice (circles). Error bars indicate standard error.
doi:10.1371/journal.ppat.0030005.g007
PLoS Pathogens | www.plospathogens.org January 2007 | Volume 3 | Issue 1 | e50032
Mouse-Adapted SARS-CoV Lethal in BALB/c Mice
stood. The histopathology documented in the mice infected
with the MA15 virus includes a rapid progression and
extensive damage to bronchiolar and alveolar epithelial cells
(Figure 6A and 6B), but it does not show some features such as
alveolar edema and hyaline membranes that were reported in
many SARS-CoV–infected patients, or in aged mice infected
with the Urbani strain of SARS-CoV [15]. This can be
explained by the relative virulence of the MA15 strain, and
the time p.i. when the lungs were evaluated. Mice infected
with the MA15 virus developed severe morbidity and died
within 3 to 5 d following infection and did not survive long
enough to show progression of the diffuse alveolar damage
seen in aged mice or in human patients, who survive for a
relatively prolonged length of time before succumbing to
complications of the acute infection. In aged mice following
SARS-CoV infection, histopathologic changes indicative of
progressive diffuse alveolar damage, including proteinaceous
deposits around alveolar walls and intraalveolar edema, are
seen beginning on day 5 [15].
The rapid progression of infection and the extensive and
persistent pulmonary replication of the virus are accompa-
nied by viremia and detection of virus in extrapulmonary
sites, suggesting that other factors may contribute to the
increased pathogenicity of the MA15 virus. A prolonged
viremic state or a secondary viremia is seen in mice infected
with MA15 and rMA15 that is not observed following
infection with the recombinant SARS-CoVs (Urbani),
rMA15SM, or rMA15ORF1ab. The MA15 virus model captures
viremia and multi-organ involvement noted in human SARS
patients [16]. However, as in all SARS cases, the primary site
of infection is the lung.
Perfusion of tissues harvested from mice in these experi-
ments was not performed, and therefore, we cannot be
certain that the detection of vRNA in various extrapulmonary
sites in MA15-inoculated mice is not due to virus carried to
and remaining in the organs and blood. However, on days 2
through 4 p.i., MA15-specific mRNAs in various tissues are
detected at a higher frequency and signal intensity than in
whole blood, and the presence of MA15 vRNA in extrap-
ulmonary tissues is detected by in situ hybridization.
Furthermore, infectious virus was detected on day 1 p.i. in
homogenates of extrapulmonary tissues when RT-PCR of
RNA from blood did not amplify any viral specific products
(Tables 3–5). Taken together, these observations support a
hypothesis that virus is present and replicating at low levels in
extrapulmonary tissues.
In BALB/c mice infected with MA15 virus or SARS-CoV,
significant lymphopenia and neutrophilia were observed
compared with pre-infection levels. MA15 virus–infected
mice had significantly greater lymphopenia and neutrophilia
than SARS-CoV–infected mice, reflecting hematological
evidence of increased disease severity following MA15 virus
infection. MA15 virus–infected mice also had significantly
higher levels of ALP than uninfected or SARS-CoV–infected
mice. Elevated levels of ALP, an enzyme found in all tissues,
but especially concentrated in the liver, may indicate cell
destruction in the liver, intestines, or other tissues. Reports of
elevated ALP levels in SARS patients are rare [17,18], but
neutrophilia and lymphopenia have been reported frequently
in human cases of SARS [19–25]. Although steroid treatment
and secondary bacterial infections may be speculated to be
the cause of neutrophilia, some patients with SARS had
neutrophilia prior to initiation of steroid treatment and in
the absence of bacterial infections [26]. Additionally, elevated
absolute neutrophil counts at presentation were independent
indicators of severe outcome of SARS in human cases
[21,27,28]. The definitive causes of lymphopenia, neutro-
philia, and elevated ALP levels have not been identified in
human cases of SARS or in this mouse model.
The mouse-adapted SARS-CoV MA15 virus will be a
valuable tool in evaluating SARS-CoV vaccines and antiviral
therapy. Quantitative virology was the only outcome measure
available in young BALB/c mice challenged with SARS-CoV
(Urbani). Because the MA15 virus replicates rapidly to high
titer and is lethal for young BALB/c mice, this virus provides a
more stringent challenge than the SARS-CoV (Urbani) virus
in evaluating the efficacy of therapeutic interventions or
prevention strategies. Prophylaxis that is able to rescue
MA15-infected mice from a lethal outcome must lower viral
burden in lungs very rapidly (e.g., within the first 24 h).
Prophylaxis that accomplishes such reduction in the burden
of MA15 virus may also reduce the severity of immunopa-
thology that follows. A reduction of immunopathology was
demonstrated in a SARS-CoV hamster model when a
monoclonal antibody specific to SARS-CoV spike protein
administered the day after infection was able to arrest a
further rise in viral titer in the lungs [29]. If similar protection
can be demonstrated against challenge with MA15 virus in
BALB/c mice, the efficacy of intervention will be well proven.
Infection of young BALB/c mice with the MA15 virus
provides a model that is small and accessible and that can be
evaluated extensively at an immunological level. Finally, and
most importantly, MA15 virus infection of young BALB/c
mice provides many elements that replicate observations in
acute (and chronic) cases of SARS infection in humans,
including sequence changes during adaptation in several
genes (nsp 5, nsp 13, S, and M); viral replication and
histopathological changes in lungs of infected animals;
viremia; detection of vRNA in extrapulmonary sites, includ-
ing the intestines; clinical indicators of illness, including
mortality; and changes in blood counts, including lympho-
penia and neutrophilia. The availability of a molecular clone
of the MA15 virus, and the ability to generate additional
SARS-CoV recombinant viruses that recapitulate the in vivo
phenotype, will allow for detailed probing of the mechanisms
mediating SARS-CoV pathogenesis and acute lung damage.
Materials and Methods
All animal and viral experiments were conducted in Biosafety
Level 3 laboratories or animal facilities, and all personnel wore
personal protective equipment, including Tyvek suits and hoods and
positive pressure HEPA-filtered air respirators. All animal protocols
employed in these studies have been approved by NIAID’s Animal
Care and Use Committee.
Serial passage of SARS-CoV in mice. A dose of 105 50% TCID50 of
SARS-CoV (Urbani) was administered intranasally to a lightly
anesthetized, 6-wk-old female BALB/c mouse in a total volume of
50 lL [30]. Two days after inoculation, the mouse was euthanized, and
its lungs were removed and homogenized with an EX-Gen Omni GLH
homogenizer (Omni International, http://www.omni-inc.com) as a
10% w/v suspension in Leibovitz’s L15 Medium (Invitrogen, http://
www.invitrogen.com), supplemented with the following antibiotics:
0.4 mg/L piperacillin (Sigma, http://www.sigmaaldrich.com), 0.1 mg/L
gentamicin (Invitrogen), and 5 mg/L amphotericin B (Quality
Biological, http://www.qualitybiological.com). The lung homogenate
was clarified by low-speed centrifugation at 2,000 rpm (650g) for 5
min, and the supernatant was administered intranasally to three
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naı¨ve mice. The process of intranasal inoculation of three female
BALB/c mice with pooled, clarified supernatants of 10% lung
homogenates collected 2 to 3 d.p.i. was repeated 14 times.
Identification of lethal phenotype and biological cloning of a lethal
virus. The supernatant from P15 lung homogenates was subjected to
three rounds of terminal dilution on Vero cells. Then, 5-fold serial
dilutions were added to cells in 96-well plates (one dilution/plate).
Two to three days later, when cytopathic effect was evident in no
more than nine wells per plate, supernatants from infected wells were
collected, diluted, and transferred to fresh monolayers of Vero cells.
After the third round of terminal dilution, 50 lL of five independent
clones were screened for lethality in four 8-wk-old female BALB/c
mice. Mortality associated with these five clones was between 50%
and 100%. One of these five clones (MA15) that caused 100% lethality
within 6 d was expanded by two more passages in Vero cells and used
in further studies.
Virus replication in the respiratory tract of mice. Young (6- to 8-
wk-old), female BALB/c mice were lightly anesthetized and inoculated
intranasally with 50 lL of serially diluted virus. For SARS-CoV
(Urbani), a dose of 105 TCID50/mouse was administered unless noted
otherwise. For lethal doses of MA15 virus, the dose administered was
equal to105.6 TCID50/mouse; for sub-lethal doses, the dose adminis-
tered was equal to 103.6 TCID50/mouse. At various time points p.i.,
mice were euthanized and tissues collected for analyses. For
determination of viral titers, tissues were homogenized to a final
10%w/v suspension in Leibovitz’s L15 Medium supplemented with
antibiotics. Tissue homogenates were clarified by low-speed centri-
fugation, and virus titers were determined in Vero cells on 24- and
96-well plates as previously described [30]. Virus titers are expressed
as TCID50/g of tissue with a lower limit of detection of 10
1.5 TCID50/g.
Purification of vRNA. Tissues homogenates were clarified by low-
speed centrifugation; supernatants were transferred to Eppendorf
tubes (http://www.eppendorf.com) and further clarified by centrifuga-
tion at 16,000g for 3 min. vRNA was extracted from 600 lL of
supernatant using the QIAamp Viral RNA Mini Kit (Qiagen, http://
www1.qiagen.com) eluted in 50lLofwater, quantifiedbymeasurement
of optical density at 280 nm on a NanoDrop ND-1000 spectropho-
tometer (NanoDrop Technologies, http://www.nanodrop.com), and
stored at80 8C.
RT-PCR and sequence analysis. First-strand cDNAs were gener-
ated by reverse transcription from RNA purified from clarified cell
supernatants of Vero cells infected with either SARS-CoV MA15,
SARS-CoV (Urbani) (P0), or from the clarified supernatants of P15
lung homogenates using reagents from the Brilliant qRT-PCR Plus
Core Reagent Kit (Stratagene, http://www.stratagene.com). In brief, 11
lL of vRNA was heat denatured at 95 8C for 2 min and quenched on
ice before addition of 10X Core RT Buffer, 0.2 lg random primers,
0.08 lmol dNTP mixture, and 20U StrataScript reverse transcriptase
for a 20-lL reaction mixture. Reverse transcription was performed
with an initial incubation of 25 8C for 10 min, followed by a 30-min
incubation at 45 8C and a 3-min denaturation at 95 8C. First-strand
cDNAs were amplified in overlapping PCR products spanning the
entire genome. Three microliters of each cDNA reaction were
amplified by PCR using the Advantage-HF PCR Kit (BD Biosciences,
http://www.bdbiosciences.com) or Herculase Enhanced DNA polymer-
ase (Stratagene) as per manufacturers’ protocols. Fifteen pairs of
primers were used to generate the overlapping PCR products (Tables
S1 and S2). Amplification products were visualized on agarose gels
and purified by use of the QIAquick Gel Extraction Kit (Qiagen). PCR
products were sequenced in both forward and reverse directions,
using 69 forward and 62 reverse primers (Table S3). Automated
sequencing was performed utilizing the BigDye Terminator version
3.1 Cycle Sequencing Kit (Applied Biosystems) as per manufacturer’s
instructions on an ABI Prism 3730 DNA Analyzer (Applied
Biosystems). Sequences were assembled and analyzed with Vector
NTI and Auto Assembler DNA Sequence Assembly Software (ABI
Prism; Applied Biosystems). When a mutation was identified in
comparison with the SARS-CoV (Urbani) published sequence,
independent RT-PCR reactions were run and subsequent RT-PCR
products were sequenced through the region containing the putative
mutation to confirm the mutation.
Detection of SARS-CoV by RT-PCR. Total RNA was isolated from
various tissues or whole blood and purified using an RNeasy Mini Kit
(Qiagen) with an on-column DNase digestion (RNase-Free DNase Set;
Qiagen), as per manufacturer’s protocol. Approximately 0.8 g of
tissue, cut into pieces no larger than 0.5 cm on any one side, was
collected into 1 mL of RNAlater (Ambion, http://www.ambion.com)
and stored at room temperature for 24 h and subsequently at 4 8C
until processed. Any unused tissue remaining after one month was
moved to 20 8C. Approximately one-half or 0.2–0.4 g of tissue was
homogenized with a disposable probe (Omni International) in 900 lL
of RLT buffer (RNeasy Mini Kit; Qiagen), supplemented with 1% (v/v)
b-mercaptoethanol (Sigma). RLT suspensions were transferred to 1.8-
mL Eppendorf microcentrifuge tubes and centrifuged at 4 8C for 3
min at 16,000g. RNA was purified further as per manufacturer’s
protocol. RNA from blood (;0.5 mL per sample) was purified using a
QIAamp RNA Blood Mini Kit (Qiagen) as per manufacturer’s
protocol with the additional DNase on-column digestion. RNAs were
quantified and 100 ng were reverse transcribed and amplified as
described above. In brief, total RNA was heat denatured at 95 8C for 2
min and quenched on ice before addition of 10X First Strand Buffer,
20U RNase Block, 0.3 lg random primers, 0.08 lmol dNTP mixture,
25U StrataScript reverse transcriptase, and water for a 20-lL
reaction. Reverse transcription was performed with an initial
incubation at 25 8C for 10 min, followed by a 30-min incubation at
45 8C and a 3-min denaturation at 95 8C. Three microliters from each
RT reaction were subsequently used in a 50-lL PCR with SARS-CoV–
specific primers for amplification of a 314-bp sequence of the
nucleocapsid gene (SARS-CoV forward (59-ggtgacggcaaaatgaaagagc-
39), SARS-CoV reverse (59-ggagaatttcccctactg-39)). b2 microglobulin
(b2M) primers were used in separate reactions as RNA quantity and
PCR controls (b2M forward (59-atgggaagccgaacatactg-39), b2M reverse
(59-cagtctcagtgggggtgaat-39)). PCR reactions were performed for a
total of 35 cycles with 50 X Advantage cDNA polymerase (Clontech,
http://www.clontech.com), 0.04 lmol dNTP mixture (Stratagene), and
10X cDNA PCR reaction buffer (Clontech) or Opti-Prime 10X Buffer
4 (Stratagene) supplemented with 0.02 lmol MgCl2 (Quality Bio-
logical) for RNA amplification of b2M and SARS-CoV, respectively
(Table S4).
Construction of SARS-CoV cDNA plasmids for reconstructing the
mouse-adapted recombinant virus rMA15. Six codon changes
(10384T.A, 10793A.C, 16177C.T, 12814A.G, 22797T.C, and
26428E.K) identified in MA15 compared with the published SARS-
CoV (Urbani) sequence, were inserted into cDNA clones and used to
construct and rescue infectious recombinant clones of SARS-CoV
(Urbani) as described previously [31]. In brief, for each mutation two
overlapping amplicons were generated by PCR, joined at primer-
introduced BsmBI sites, and ligated into a cDNA of icSARS-CoV
using two unique restriction sites that flanked the mutation of
interest. PCR reactions were performed with Expand Long Taq
(Roche Applied Sciences, http://www.roche-applied-science.com) in
30 cycles of 94 8C for 30 s, 55 8C for 30 s, and extensions at 68 8C for 1
min using the following primers on plasmids encoding portions of
the icSARS-CoV genome: for the mutation at nucleotide position
10384, primer pairs 59-10124 (59-CATGT CATTT GCACA GCAG) and
39-10364C (59-ATTAG GTCTC ATGGC ACAC) and 59-10384T.A (59-
AGACC TAATT ATACC ATTAA AG) and 39-11091C (59-CAAGC
ACAAG AATGC GTGC) were used. A second PCR amplification
using primers 59-10124 and 39-11091C produced a PCR product that
was digested with the appropriate restriction enzymes (BglII, Mfe1)
and ligated into the icSARS-CoV cDNA plasmid. Similarly, the 10793
mutation was constructed using primer pairs 59-10124 and 39-10770C
(59-CTTTC AAAGC AGCAC ACATA TC) and 59-10793A.C (59-
GAAAG CGCTG CTGCA GAATG) and 39-11091C, followed by
amplification with primers 59-10124 and 39-11091C. This PCR
product was digested with the appropriate restriction enzymes (BglII
and Mfe1) and ligated into the icSARS-CoV cDNA plasmid. The
12814 mutation was similarly constructed using the primer pairs 59-
M13R3 and 39-SARS D mu1() (59-NNNCG TCTCG TTCCA GTTCT
GCGTA AATTG TACCT GTACC) and 59 SARS Dmu1(þ) (59-NNNCG
TCTCT GGAAC CACCT TGTAG GTTTG) and 39 D1500() (59-
CCCTG TAGAC GACAT CAGTAC). The two resulting amplicons
were joined following digestion (with BsmBI) and purification
(QIAquick PCR Purification Kit; Qiagen). The product DNA was
digested with BamHI and AclI and inserted into an icSARS-CoV
cDNA. The 16177 mutation was constructed using primers 59-16004
(59-CATCCTAATCAGGAGTATGC) and 39-16157C (59-CACCTA-
CAGCCTGCAAGAC) and pr ime r s 5 9- 1 6177C.T ( 5 9-
GCTGTAGGTGTTTGTGTATTG) and 39-18044C (CTTTATAT-
CAACGCTGAGGTG). Primers 59-16004 and 39-18044C were used to
amplify the appropriate fragment that was purified and digested with
PflMI and BbvCI, and ligated into an icSARS-CoV cDNA. The 22797
mutation was constructed using primer pairs 59 #38 (59-AGAGG
AACTG CTGTA ATGTC TC) and 39 SMAS MuS() (59-NNNCG
TCTCT ATGAT TACCA GTTGA AGTAG CATC) and 59 SMAS
SMuS(þ) (59-NNNCG TCTCA TCATAA TTATA AATAT AGGTA
TCTTA GACAT GG) and 39 SARS E 4592() (59-CTAGC ACAAA
TGCCA GCTCC). The two resulting amplicons were joined following
digestion (with BsmBI) and purification and ligation. The full-length
product was digested and inserted into an icSARS-CoV cDNA
PLoS Pathogens | www.plospathogens.org January 2007 | Volume 3 | Issue 1 | e50034
Mouse-Adapted SARS-CoV Lethal in BALB/c Mice
utilizing restriction endonuclease sites AgeI and SalI. The 26428
mutation was constructed using primer sets 59 #44 (59-
TGATCCTCTGCAACCTGAGC) and 39 SMAS MuM() (59-
NNNCGTCTCACGGTAATAGTACCGTTGTCTGC) and 59 SMAS
MuM(þ) (59-NNNCGTCTCTACCGTTGAGAAGCTTAAACAACTCC)
and 39 SARS X5() (59-NNNNNTTAATTAATTAATTTGTTCGTT-
TATTTAAAACAACA). Resulting amplicons were ligated following
digestion with BsmBI. The mutation-containing product was digested
and inserted into an icSARS-CoV cDNA at SwaI and NdeI restriction
sites. In all cases, the final plasmids and the mutations in the plaque-
purified viruses were verified by RT-PCR and sequencing.
Assembly of full-length cDNAs and recovery of recombinant
viruses. The full-length cDNAs of wild-type SARS-CoV (icSARS-
CoV) or mouse-adapted SARS-CoV recombinants were produced as
previously described [31]. RNA transcripts from full-length cDNAs
were added to 800 ll of the Vero E6 cell suspension (8.03 106) in an
electroporation cuvette and four electrical pulses of 450 V at 50 lF
were given with a Gene Pulser II electroporator (Bio-Rad, http://www.
bio-rad.com) similar to protocols previously described [32,33]. The
presence of full-length cDNAs and transcripts was verified by
separation on agarose gels and visualization by UV light. The
transfected Vero E6 cells were seeded in a 75-cm2 flask and incubated
at 37 8C for 2 d. Viruses were plaque purified in Vero E6 cells.
In vitro growth of recombinant viruses. SARS-CoV (Urbani),
icSARS-CoV (Urbani infectious clone), rMA15 (icSARS-CoV with all
six mutations found in MA15), rMA15ORF1ab (icSARS-CoV with the
four mutations found in the replicase genes of MA15 ORF 1ab), and
rMA15SM (icSARS-CoV with the two mutations found in the
structural genes of MA15 S and M) viruses were propagated on Vero
E6 cells in Eagle’s MEM supplemented with 10% fetal calf serum,
kanamycin (0.25 lg/ml), and gentamicin (0.05 lg/ml) at 37 8C in a
humidified CO2 incubator. Cultures of Vero E6 cells were infected in
duplicate at an MOI of 0.1 for 1 h. Cell monolayers were washed twice
with 2 mL of PBS and overlaid with complete MEM. Supernatants
were collected at various times p.i. and virus was quantified by plaque
assay on Vero E6 cells in 60 mm2 dishes. Plaques were visualized by
neutral red staining and counted at 48 h.
Northern blot analysis. Cultures of Vero E6 cells were inoculated
with SARS-CoV viruses at an MOI of 1 and incubated for 1 h at 37 8C.
At 10.5 h.p.i., intracellular RNA was isolated using TRIzol Reagent
(Invitrogen) as directed by the manufacturer, and 0.1 lg of total
mRNA was treated with glyoxal and separated on agarose gels using
NorthernMax-Gly according to the manufacturer’s directions (Am-
bion). The RNA was transferred to BrightStar-Plus membrane
(Ambion) for 3.5 h and then cross-linked to the membrane by UV
light. The blot was prehybridized and probed with an N gene–specific
oligodeoxynucleotide probe (59-CTTGACT GCCGCCT CTGCTbTbCCCTbCTb
GCb-39), where biotinylated nucleotides are designated with a sub-
script b. Blots were hybridized overnight, and washed with low and
high stringency buffers as recommended by the manufacturer. Filters
were incubated with strepavidin-AP, washed, and then incubated with
chemiluminescent substrate CDP-STAR (Ambion). The blots were
overlaid with film and developed.
Western blot analysis. Ten hours p.i. with SARS-CoV (Urbani),
MA15 (the biologically derived clone), icSARS-CoV, rMA15, rMA15OR-
F1ab, or rMA15SM cells were washed once in PBS and lysed in buffer
containing 20 mM Tris-HCL (pH 7.6), 150 mM NaCl, 0.5% deoxycho-
line, 1% nonidet-p-40, and 0.1% sodium dodecyl sulphate (SDS).
Supernatants clarified of nuclei were added to an equal volume of 5
mM EDTA/0.9% SDS, resulting in a final SDS concentration of 0.5%,
and samples were heat inactivated for 30 min at 90 8C prior to transfer
to Biosafety Level 2. After transfer to Biosafety Level 2, samples were
again heat inactivated for 30 min at 90 8C before use. Equivalent
sample volumes were loaded onto 7.5% Ready Gels (Bio-Rad) and
transferred to a PVDF membrane (Bio-Rad). For detecting SARS-CoV
antigens, blots were probed with polyclonal mouse antisera directed
against Venezuelan equine encephalitis virus replicon particles (VRPs)
that expressed the SARS-CoV ORF 3a (VRP-ORF3a), S (VRP-S), or N
(VRP-N) proteins diluted 1:200 for SARS-CoV ORF 3a and 1:500 for S
and N antisera. Dilutions were done in 5% blotto in PBS/0.5% Tween
20 and developed using ECL chemiluminescence reagents (Amersham,
http://www.amershambiosciences.com).
In situ hybridization. Paraffin-embedded sections, 5-mm thick,
were probed with 35S UTP-labeled riboprobes complementary to the
N gene of SARS-CoV (Urbani) or the Sindbis virus genome, as a
negative control, using previously described methods [34]. In brief,
following treatment to prevent nonspecific probe binding, the tissues
were incubated overnight with either probe at 5 3 104 cpm/lL in
hybridization buffer at 42 8C. The slides were then washed,
dehydrated, and coated with NBT emulsion (Eastman Kodak, http://
www.kodak.com), and incubated at 80 8C for 5 d prior to develop-
ment. Positive signal, as determined by silver grain deposition, was
evaluated by light microscopy.
Statistics. Log-transformed virus titers were compared in a Mann-
Whitney U test, and statistical significance was assigned to differences
with p-values ,0.05.
Histopathology and immunohistochemistry. Lungs, liver, spleen,
thymus, and brain were obtained from individual mice euthanized at
various time points, fixed in 10% neutral buffered formalin, and
processed for histopathologic and IHC examination as described
[35,36]. Tissue sections (3 lm) were stained with hematoxylin and
eosin and by using an immunoalkaline phosphatase technique with a
hyperimmune rabbit anti-SARS-CoV nucleocapsid protein antibody
at a dilution of 1/1000.
Supporting Information
Figure S1. In Vitro Single-Cycle Growth Analysis of Recombinant
SARS-CoVs and MA15 Virus
Cultures of Vero E6 cells were infected at an MOI of 0.1 with
indicated viruses in duplicate. Supernatants were collected at 1, 5, 13,
23, and 36 h.p.i., and virus was quantified by plaque assay in Vero E6
cells. Plaques were visualized by neutral red staining and counted at
48 h. SARS-CoV (Urbani) and rMA15SM replicate similarly to icSARS-
CoV (unpublished data). Data points represent means of samples
measured in duplicate. A repeat experiment demonstrated similar
growth kinetics (unpublished data). Diamonds, icSARS-CoV; squares,
MA15; circles, rMA15; and triangles, rMA15ORF1ab.
Found at doi:10.1371/journal.ppat.0030005.sg001 (28 KB PDF).
Figure S2. In Vivo Replication of Recombinant SARS-CoVs in BALB/c
Mice
Groups of four mice were inoculated intranasally with 50 lL of
recombinant viruses icSARS-CoV, rMA15SM, rMA15ORF1ab, rMA15, or
MA15 and sacrificed on (A) day 2 p.i. or (B) day 4 p.i. Lungs and sera
were collected for viral titration. Virus titers are expressed as log10
pfu/g lung (circles) or log10 pfu/mL serum (squares) from individual
mice; bars represent the geometric mean for the group. Limits of
detection for viral titers from lung and sera are 250 pfu/mL and 50
pfu/mL, respectively.
Found at doi:10.1371/journal.ppat.0030005.sg002 (35 KB PDF).
Figure S3. In Situ Hybridization of SARS-CoV RNA in Lungs of
BALB/c Mice
BALB/c mice were infected with SAR-CoV (Urbani), rMA15SM,
rMA15ORF1ab, rMA15, or MA15 virus. Lungs were harvested on days
2 and 4 p.i., and in situ hybridization was performed as described in
Materials and Methods. No specific signal was observed with a control
riboprobe at any time point, while SARS-CoV–N specific signal was
readily apparent within the lungs for all five viruses at day 2 p.i. In
contrast, at day 4 p.i., abundant SARS-CoV–specific in situ signal was
observed in lungs of mice infected with the lethal MA15 virus or the
lethal recombinant rMA15, but not in lungs of mice infected with the
non-lethal sub-clones or SARS-CoV (Urbani).
Found at doi:10.1371/journal.ppat.0030005.sg003 (6.7 MB PDF).
Table S1. PCR Primers
Found at doi:10.1371/journal.ppat.0030005.st001 (35 KB DOC).
Table S2. PCR Thermal Profiles
Found at doi:10.1371/journal.ppat.0030005.st002 (46 KB DOC).
Table S3. Sequencing Primers
Found at doi:10.1371/journal.ppat.0030005.st003 (44 KB DOC).
Table S4. PCR Thermal Profiles Used for Detection of SARS-CoV
Found at doi:10.1371/journal.ppat.0030005.st004 (36 KB DOC).
Table S5. Lymphopenia, Neutrophilia, and Elevated ALP in Mice
Inoculated with SARS-CoV and MA15 Virus
Found at doi:10.1371/journal.ppat.0030005.st005 (149 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for the viruses and sequences discussed in this paper are mouse-
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adapted SARS-CoV MA15 sequence (DQ497008) and SARS-Cov
(Urbani) (AY278741).
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